DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Hexalen (Altretamine) - Indications and Dosage

 
 



INDICATIONS and USAGE

HEXALEN® (altretamine) capsules is indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.

DOSAGE AND ADMINISTRATION

HEXALEN® capsules is administered orally. Doses are calculated on the basis of body surface area.

HEXALEN® capsules may be administered either for 14 or 21 consecutive days in a 28 day cycle at a dose of 260 mg/m2/day. The total daily dose should be given as 4 divided oral doses after meals and at bedtime. There is no pharmacokinetic information supporting this dosing regimen and the effect of food on HEXALEN® capsules bioavailability or pharmacokinetics has not been evaluated.

HEXALEN® capsules should be temporarily discontinued (for 14 days or longer) and subsequently restarted at 200 mg/m2/day for any of the following situations:
  1) Gastrointestinal intolerance unresponsive to symptomatic measures;
  2) White blood count <2000/mm3 or granulocyte count <1000/mm3;
  3) Platelet count <75,000/mm3;
  4) Progressive neurotoxicity.

If neurologic symptoms fail to stabilize on the reduced dose schedule, HEXALEN® capsules should be discontinued indefinitely.

Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published (2-9). There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

HOW SUPPLIED

HEXALEN® (altretamine) capsules is available in 50 mg clear, hard gelatin capsules imprinted with the following inscription:
USB 001.

Bottles of 100 capsules
(NDC 62856-001-10)

Store up to 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017